Literature DB >> 25830650

Impact of daptomycin resistance on Staphylococcus aureus virulence.

David R Cameron1, Lawrence I Mortin, Aileen Rubio, Eleftherios Mylonakis, Robert C Moellering, George M Eliopoulos, Anton Y Peleg.   

Abstract

Daptomycin resistance (DAP(R)) in Staphylococcus aureus is associated with mutations in genes that are also implicated in staphylococcal pathogenesis. Using a laboratory-derived series of DAP exposed strains, we showed a relationship between increasing DAP MIC and reduced virulence in a Galleria mellonella infection model. Point mutations in walK and rpoC led to cumulative reductions in virulence and simultaneous increases in DAP MIC. A point mutation to mprF did not impact on S.aureus virulence; however deletion of mprF led to virulence attenuation and hyper-susceptibility to DAP. To validate our findings in G. mellonella, we confirmed the attenuated virulence of select isolates from the laboratory-derived series using a murine septicaemia model. As a corollary, we showed significant virulence reductions for clinically-derived DAP(R) isolates compared to their isogenic, DAP-susceptible progenitors (DAP(S)). Intriguingly, each clinical DAP(R) isolate was persistent in vivo. Taken together, it appears the genetic correlates underlying daptomycin resistance in S. aureus also alter pathogenicity.

Entities:  

Keywords:  Galleria mellonella; S. aureus; bacterial persistence; mprF; walK

Mesh:

Substances:

Year:  2015        PMID: 25830650      PMCID: PMC4601193          DOI: 10.1080/21505594.2015.1011532

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  16 in total

1.  LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF.

Authors:  Aileen Rubio; Jeff Moore; Mustafa Varoglu; Mary Conrad; Min Chu; Walter Shaw; Jared A Silverman
Journal:  Mol Membr Biol       Date:  2012-01-26       Impact factor: 2.857

2.  Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Authors:  Lisa Friedman; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin.

Authors:  O Gasch; M Camoez; M A Domínguez; B Padilla; V Pintado; B Almirante; C Martín; F López-Medrano; E Ruiz de Gopegui; J R Blanco; G García-Pardo; E Calbo; M Montero; A Granados; A Jover; C Dueñas; M Pujol
Journal:  J Antimicrob Chemother       Date:  2013-10-09       Impact factor: 5.790

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.

Authors:  Soo-Jin Yang; Cynthia C Nast; Nagendra N Mishra; Michael R Yeaman; Paul D Fey; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

6.  Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection.

Authors:  Wei Gao; Kyra Chua; John K Davies; Hayley J Newton; Torsten Seemann; Paul F Harrison; Natasha E Holmes; Hyun-Woo Rhee; Jong-In Hong; Elizabeth L Hartland; Timothy P Stinear; Benjamin P Howden
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

7.  Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection.

Authors:  Anton Y Peleg; Divya Monga; Satish Pillai; Eleftherios Mylonakis; Robert C Moellering; George M Eliopoulos
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

8.  Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

Authors:  Anton Y Peleg; Spiros Miyakis; Doyle V Ward; Ashlee M Earl; Aileen Rubio; David R Cameron; Satish Pillai; Robert C Moellering; George M Eliopoulos
Journal:  PLoS One       Date:  2012-01-06       Impact factor: 3.240

9.  Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.

Authors:  Benjamin P Howden; Christopher R E McEvoy; David L Allen; Kyra Chua; Wei Gao; Paul F Harrison; Jan Bell; Geoffrey Coombs; Vicki Bennett-Wood; Jessica L Porter; Roy Robins-Browne; John K Davies; Torsten Seemann; Timothy P Stinear
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

10.  The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion.

Authors:  Christoph M Ernst; Petra Staubitz; Nagendra N Mishra; Soo-Jin Yang; Gabriele Hornig; Hubert Kalbacher; Arnold S Bayer; Dirk Kraus; Andreas Peschel
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more
  11 in total

Review 1.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

2.  A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.

Authors:  Jieun Kwon; Tina Mistry; Jinhong Ren; Michael E Johnson; Shahila Mehboob
Journal:  Bioorg Med Chem       Date:  2017-11-11       Impact factor: 3.641

3.  Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?

Authors:  J Ruiz-Ramos; P Vidal-Cortés; A Díaz-Lamas; R Reig-Valero; F Roche-Campo; M Del Valle-Ortiz; X Nuvials-Casals; M Ortiz-Piquer; D Andaluz-Ojeda; L Tamayo-Lomas; M A Blasco-Navalpotro; M Rodriguez-Aguirregabiria; J Aguado; P Ramirez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-04       Impact factor: 3.267

4.  Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.

Authors:  Kristoffer T Bæk; Louise Thøgersen; René G Mogenssen; Maiken Mellergaard; Line E Thomsen; Andreas Petersen; Søren Skov; David R Cameron; Anton Y Peleg; Dorte Frees
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

5.  Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant Staphylococcus aureus and potentiates the activity of gentamicin.

Authors:  Tatiana Johnston; Gabriel Lambert Hendricks; Steven Shen; Roy Fangxing Chen; Bumsup Kwon; Michael John Kelso; Wooseong Kim; Beth Burgwyn Fuchs; Eleftherios Mylonakis
Journal:  Future Med Chem       Date:  2016-09-21       Impact factor: 3.808

6.  Daptomycin Tolerance in the Staphylococcus aureus pitA6 Mutant Is Due to Upregulation of the dlt Operon.

Authors:  Lukas Mechler; Eve-Julie Bonetti; Sebastian Reichert; Matthias Flötenmeyer; Jacques Schrenzel; Ralph Bertram; Patrice François; Friedrich Götz
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  Stenotrophomonas maltophilia Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient.

Authors:  Arianna Pompilio; Valentina Crocetta; Dipankar Ghosh; Malabika Chakrabarti; Giovanni Gherardi; Luca Agostino Vitali; Ersilia Fiscarelli; Giovanni Di Bonaventura
Journal:  Front Microbiol       Date:  2016-09-30       Impact factor: 5.640

8.  Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus.

Authors:  Zhuo Ma; Erica Lasek-Nesselquist; Jackson Lu; Ryan Schneider; Riddhi Shah; George Oliva; Janice Pata; Kathleen McDonough; Manjunath P Pai; Warren E Rose; George Sakoulas; Meenakshi Malik
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

9.  VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Infection.

Authors:  Agustina Taglialegna; Maria C Varela; Roberto R Rosato; Adriana E Rosato
Journal:  mSphere       Date:  2019-02-13       Impact factor: 4.389

Review 10.  More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin.

Authors:  Declan Alan Gray; Michaela Wenzel
Journal:  Antibiotics (Basel)       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.